{
    "ticker": "ELDN",
    "name": "Eledon Pharmaceuticals, Inc.",
    "description": "Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for patients with serious diseases. Founded in 2018, Eledon focuses on advancing its proprietary platform of biologics targeting the immune system to address unmet medical needs in areas such as kidney disease and neurodegeneration. The company is particularly known for its lead product candidate, ELD-101, which is being evaluated for the treatment of kidney diseases characterized by excessive protein leakage. Eledon employs a robust scientific approach, leveraging insights from immunology and cell biology to create therapies that modulate the immune response. The company's mission is to improve patient outcomes and quality of life through the development of next-generation therapeutic options. With a strong pipeline and a commitment to scientific excellence, Eledon is poised to make significant contributions to the field of medicine and offers hope to patients with debilitating conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2018",
    "website": "https://www.eledon.com",
    "ceo": "David A. H. H. H. Mott",
    "social_media": {
        "twitter": "https://twitter.com/EledonPharma",
        "linkedin": "https://www.linkedin.com/company/eledon-pharmaceuticals/"
    },
    "investor_relations": "https://ir.eledon.com",
    "key_executives": [
        {
            "name": "David A. H. H. H. Mott",
            "position": "CEO"
        },
        {
            "name": "James P. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "ELD-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "Eledon Pharmaceuticals, Inc. | Innovative Biopharmaceuticals",
        "meta_description": "Explore Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing innovative immune-modulating therapies for serious diseases.",
        "keywords": [
            "Eledon Pharmaceuticals",
            "Biopharmaceuticals",
            "Kidney Disease",
            "Neurodegeneration",
            "ELD-101"
        ]
    },
    "faq": [
        {
            "question": "What does Eledon Pharmaceuticals focus on?",
            "answer": "Eledon Pharmaceuticals focuses on developing innovative therapies for serious diseases, particularly those involving the immune system."
        },
        {
            "question": "What is ELD-101?",
            "answer": "ELD-101 is Eledon's lead product candidate aimed at treating kidney diseases characterized by excessive protein leakage."
        },
        {
            "question": "Where is Eledon headquartered?",
            "answer": "Eledon is headquartered in San Diego, California, USA."
        },
        {
            "question": "When was Eledon Pharmaceuticals founded?",
            "answer": "Eledon Pharmaceuticals was founded in 2018."
        }
    ],
    "competitors": [
        "BMY",
        "AMGN",
        "GILD",
        "VRTX"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRNA",
        "ABBV"
    ]
}